Welcome to our dedicated page for Acurx Pharmaceuticals news (Ticker: ACXP), a resource for investors and traders seeking the latest updates and insights on Acurx Pharmaceuticals stock.
Acurx Pharmaceuticals, Inc. develops small-molecule antibiotics for difficult-to-treat bacterial infections through a Gram-positive selective spectrum approach targeting DNA polymerase IIIC. Its pipeline includes ibezapolstat for Clostridioides difficile infection and additional DNA pol IIIC inhibitor candidates directed at Gram-positive pathogens such as MRSA, VRE, drug-resistant Streptococcus pneumoniae and B. anthracis.
Recurring ACXP news covers antibiotic development updates, microbiome data, scientific conference presentations, intellectual property for DNA pol IIIC inhibitors, financial results, registered offerings, warrant activity and investor-presentation announcements.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced on March 30, 2026 that the Korean Intellectual Property Office granted a patent covering DNA Polymerase IIIC inhibitors, including compositions‑of‑matter, methods of use, and pharmaceutical formulations.
This grant adds to Acurx's expanding patent estate protecting its ACX‑375C program, following four U.S. patents and granted patents in Israel, Japan, India, Australia, and other jurisdictions. The company said its lead DNA pol IIIC inhibitor, ibezapolstat, is positioned to enter international Phase 3 pivotal registration trials in the U.S. and EU for oral acute C. difficile infection and that a trial in multiply‑recurrent CDI is starting up.
Acurx Pharmaceuticals (NASDAQ: ACXP) reported full-year 2025 results and a business update on March 13, 2026. Key items: cash $7.6M, gross equity-line proceeds ~$4.0M in 2025, net loss $8.0M for 2025, and 2,348,113 shares outstanding.
Clinical highlights include a planned open-label 20-patient rCDI pilot, Phase 2 ibezapolstat results (96% clinical cure of 26 patients, no recurrence), a new USPTO patent to Dec 2039, and structural biology publication supporting the Pol IIIC inhibitor program.
Acurx (Nasdaq: ACXP) announced a new open-label pilot trial of ibezapolstat in multiply-recurrent C. difficile infection (rCDI) and said its broader CDI program is ready to advance to Phase 3 international trials, subject to funding.
Key details: up to 20 patients in the pilot, first patient expected to enroll in Q4 2026, prior Phase 2 results showed high clinical cure and low recurrence, and Acurx holds FDA QIDP and Fast-Track plus EMA SME designations.
Acurx Pharmaceuticals (NASDAQ: ACXP) will report full year and fourth quarter 2025 financial results on Friday, March 13, 2026 at 8:00 a.m. ET before U.S. markets open. Management will host a conference call to review results and provide a business update.
Call hosts: David P. Luci, President and CEO, and Robert G. Shawah, CFO. Toll-free U.S. access and international participant numbers are provided for investors.
Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the USPTO granted U.S. patent US 12,534,470 covering DNA Polymerase IIIC inhibitors, including compositions, methods of use, and pharmaceutical formulations. This adds to four U.S. patents and granted patents in Israel, Japan, India, and Australia.
The company says its lead DNA pol IIIC inhibitor, ibezapolstat, is Phase 3-ready for oral C. difficile treatment, and preclinical compounds show microbiome selectivity versus linezolid and systemic absorption supporting potential oral and parenteral use across multiple serious infection indications.
Acurx Pharmaceuticals (Nasdaq: ACXP) announced on Nov 18, 2025 that Health~Holland awarded a research grant of approximately $375,000 to Leiden University Medical Center and, via a three-party consortium, to Acurx to fund POLSTOP4MDRO.
The project will extend prior LUMC–Acurx structural biology work that produced three PolC structures (apo, with ibezapolstat and with ACX-801) and kinetic data versus MRSA, VRE and PRSP. The new work aims to generate the first 3D structure of PolC from MRSA bound to an Acurx inhibitor and to study conservation of mode-of-action and resistance across Gram-positive multidrug-resistant pathogens. The release notes ibezapolstat is Phase 3–ready and mentions Acurx's preclinical program for inhalational anthrax.
Acurx Pharmaceuticals (NASDAQ: ACXP) reported third-quarter 2025 results and operational updates on Nov 12, 2025. Key items: a 1-for-20 reverse stock split on Aug 4, 2025 restored Nasdaq minimum bid-price compliance on Aug 26, 2025 and the company now meets Nasdaq equity thresholds. The Australian patent for DNA polymerase IIIC inhibitors was granted in Sep 2025, joining prior U.S., Israeli, Japanese and Indian patents covering ACX-375C.
Cash totaled $5.9M at Sep 30, 2025; recent financings raised ~$1.7M (equity line) plus ~$1.4M from warrant exercises. Q3 R&D and G&A declined versus prior year; net loss was $2.0M for Q3 2025.
Acurx Pharmaceuticals (NASDAQ: ACXP) reported publication in Nature Communications demonstrating for the first time structural evidence of its DNA pol IIIC inhibitor, ibezapolstat, bound to its bacterial target.
The release highlights Phase 2 clinical results for ibezapolstat in C. difficile infection: 96% initial cure and no recurrence, and states the program is Phase 3 ready in the U.S. and EU. Ibezapolstat previously received FDA QIDP and Fast-Track designations and EMA SME designation. Acurx also describes a preclinical oral pipeline for ABSSSI and HAP/VAP and parallel planning for an inhaled anthrax program.
Acurx Pharmaceuticals (NASDAQ: ACXP) presented new data at IDWeek 2025 (Oct 19-22, 2025) showing its Phase 3-ready DNA pol IIIC inhibitor ibezapolstat (IBZ) exhibits selective antibacterial activity in the gut that spares bile acid-metabolizing bacteria, a profile linked to IBZ's anti-recurrence effect in C. difficile infection where no patient cured in Phase 2 experienced recurrence.
New preclinical colonic microbiome data in a mouse model suggest representative DNA pol IIIC inhibitor compounds may share this microbiome-sparing class effect compared with linezolid. Ibezapolstat has FDA QIDP and Fast-Track designation; Acurx's preclinical candidates are QIDP/Fast-Track eligible for systemic Gram-positive infections.
Acurx Pharmaceuticals (NASDAQ: ACXP) will discuss its third quarter 2025 financial results on Wednesday, November 12, 2025 at 8:00 a.m. ET before U.S. markets open.
David P. Luci, President and CEO, and Robert G. Shawah, CFO, will host a conference call to review the results and provide a business update. Toll-free U.S. dial-in is 1-877-790-1503 with Conference ID 13756868; international participant numbers are available via the company’s conferencing link.